Key result
Perioperative acute kidney injury remains a serious complication with high mortality, and while novel biomarkers are emerging, management remains primarily preventive without proven therapeutic interventions.
Perioperative AKI is a serious complication with high mortality, and while novel biomarkers show promise for early detection, management remains largely preventive with no definitive pharmacological therapies currently supported by clear evidence.
Answers are grounded in this paper and cite their sources.
Prioritize preventive strategies for perioperative AKI; leaves open effective therapies and biomarker validation.
Acute kidney injury (AKI) is a serious complication in the perioperative period, and is consistently associated with increased rates of mortality and morbidity. Two major consensus definitions have been developed in the last decade that allow for easier comparison of trial evidence. Risk factors have been identified in both cardiac and general surgery and there is an evolving role for novel biomarkers. Despite this, there has been no real change in outcomes and the mainstay of treatment remains preventive with no clear evidence supporting any therapeutic intervention as yet. This review focuses on definition, risk factors, the emerging role of biomarkers and subsequent management of AKI in the perioperative period, taking into account new and emerging strategies.
No takes yet. Share an insight, caveat, or question.
Calvert et al. (2012) conducted a review in Perioperative acute kidney injury. Perioperative acute kidney injury remains a serious complication with high mortality, and while novel biomarkers are emerging, management remains primarily preventive without proven therapeutic interventions.
Synapse has enriched 10 related papers. Consider them for comparative context: